Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21349700 | 0.85 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2POLBNPC1 | |
| SCHEMBL26040460 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL21348932 | 0.82 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL31320124 | 0.82 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL21326570 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL30104719 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL28906480 | 0.81 | PLA2G2A (0.40) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31752906 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL30931812 | 0.77 | PLA2G2A (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL21551592 | 0.77 | PLA2G2A (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221700-A | Condensed ring aromatic compound, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115867542-A | Novel benzimidazole compounds | 微境生物医药科技(上海)有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115304623-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022002100-A1 | NOVEL BENZIMIDAZOLE COMPOUND | 微境生物医药科技(上海)有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-113880804-A | Novel benzimidazole compounds | 微境生物医药科技(上海)有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| CN-112513017-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3535267-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | KDM4E 1504/4885ALDH1A1 404/4885HPGD 399/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | KDM4E 1414/4885ALDH1A1 317/4885HPGD 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.